Ir a la página de inicio del Gobierno del Principado de Asturias

Datos del Documento

Utilice este identificador para citar o enlazar este documento:

Título: Cisplatin resistance in cell models: evaluation of metallomic and biological predictive biomarkers to address early therapy failure
Autores: Espina, Marta
Corte Rodríguez, Mario
Aguado, Leticia
Montes Bayón, María
Sierra, Marta
Martínez Camblor, Pablo
Blanco González, Elisa
Sierra Zapico, Luisa María
Fecha Edición: 7-Abr-2017
Editor: The Royal Society of Chemistry
Cita Bibliográfica: Marta Espina, Mario Corte-Rodríguez, Leticia Aguado, María Montes-Bayón, Marta I. Sierra, Pablo Martínez-Camblor, Elisa Blanco-González, L. María Sierra. Metallomics. 2017; 9: 564-574
Resumen: Cisplatin, one of the most extensively used metallodrugs in cancer treatment, presents the important drawback of patient resistance. This resistance is the consequence of different processes including those preventing the formation of DNA adducts and/or their quick removal. Thus, a tool for the accurate detection and quantitation of cisplatin-induced adducts might be valuable for predicting patient resistance. To prove the validity of such an assumption, highly sensitive plasma mass spectrometry (ICP-MS) strategies were applied to determine DNA adduct levels and intracellular Pt concentrations. These two metal-relative parameters were combined with an evaluation of biological responses in terms of genomic stability (with the Comet assay) and cell cycle progression (by flow cytometry) in four human cell lines of different origins and cisplatin sensitivities (A549, GM04312, A2780 and A2780cis), treated with low cisplatin doses (5, 10 and 20 mM for 3 hours). Cell viability and apoptosis were determined as resistance indicators. Univariate linear regression analyses indicated that quantitation of cisplatin-induced G–G intra-strand adducts, measured 1 h after treatment, was the best predictor for viability and apoptosis in all of the cell lines. Multivariate linear regression analyses revealed that the prediction improved when the intracellular Pt content or the Comet data were included in the analysis, for all sensitive cell lines and for the A2780 and A2780cis cell lines, respectively. Thus, a reliable cisplatin resistance predictive model, which combines the quantitation of adducts by HPLC-ICP-MS, and their repair, with the intracellular Pt content and induced genomic instability, might be essential to identify early therapy failure.
Aparece en las Colecciones:Open Access DRIVERset

Archivos en este documento:

Archivo TamañoFormato
Archivo.pdf1,86 MBAdobe PDFVer/Abrir

Todos los documentos en RIA están protegidos por derechos de autor.

Valid XHTML 1.0! DSpace Software Copyright © 2002-2007 MIT and Hewlett-Packard - Contacto